- Open Access
Genome-wide expression patterns of invasion front, inner tumor mass and surrounding normal epithelium of colorectal tumors
© Staub et al; licensee BioMed Central Ltd. 2007
- Received: 30 September 2007
- Accepted: 14 December 2007
- Published: 14 December 2007
Colorectal tumors have characteristic genome-wide expression patterns that allow their distinction from normal colon epithelia and facilitate clinical prognosis. The expression heterogeneity within a primary colorectal tumor has not been studied on a genome scale yet. Here we investigated three compartments of colorectal tumors, the invasion front, the inner tumor mass, and surrounding normal epithelial tissue by microdissection and microarray-based expression profiling. In both tumor compartments many genes were differentially expressed when compared to normal epithelium. The sets of significantly deregulated genes in both compartments overlapped to a large extent and revealed various interesting known and novel pathways that could have contributed to tumorigenesis. Cells from the invasion front and inner tumor mass, however, did not show significant differences in their expression profile, neither on the single gene level nor on the pathway level. Instead, gene expression differences between individuals are more pronounced as all patient-matched tumor samples clustered in close proximity to each other. With respect to invasion front and inner tumor mass we conclude that the specific tumor cell micro-environment does not have a strong influence on expression patterns: largely similar genome-wide expression programs operate in the invasion front and interior compartment of a colorectal tumor.
- Colorectal Tumor
- Invasion Front
- Gene Expression Difference
- Primary Colorectal Tumor
Recent reports have highlighted differences between the invasion front and interior compartments of colorectal tumors. Tumor cell budding at the invasion front is increasingly recognized as an adverse prognostic factor for colorectal tumors [1, 2]. Hypoxia in the inner tumor mass is thought to induce angiogenesis through changes in hypoxia inducible factor-regulated gene transcription  and to induce epithelial-mesenchymal transition . Downstream targets of the Wnt/beta-catenin pathway and beta-catenin itself exhibit stronger protein expression at the invasion front of colon tumors [5–8]. However, recent success in the prediction of metastatic properties of tumors from genome-wide expression profiles of whole tumors [9, 10] suggest that the capability to metastasize is imprinted in the expression programs of the majority of primary tumor cells, not only those at the invasion front. It is not clear whether the reported enhanced protein expression of some Wnt/beta-catenin pathway targets is also reflected on the level of transcription. In general, little is known about how similar the genomes of cells in different tumor compartments are and even less is known about the differences in their gene expression programs.
This motivated us to study the expression of the invasion front, inner cells and surrounding normal epithelia of primary colorectal tumors by laser-capture microdissection and genome-wide microarray expression analysis. To our knowledge this is the first study of expression heterogeneity of a primary tumor on a genome scale. Cells from distinct tumor compartments were separated by laser-capture microdissection (documented electronic images are available upon request). RNA amplification was necessary to obtain sufficient starting material for hybridization of Affymetrix U133A DNA chips. For methodological details we refer to our previous work [11–13]. We investigated the expression data by unsupervised multivariate data mining techniques, statistical group testing and further explored the results by the use of different pathway/gene group analysis algorithms and databases.
The analyses so far neither do reveal how strong gene expression differences between tumor and normal cells are, nor do they allow to conclude that there are any significant expression changes between tumor compartments at all. To investigate the strengths of expression differences among sample groups we performed statistical tests. In comparisons of the normal epithelium with interior tumor cells we found 1528 of 7433 genes under investigation (see Additional files 1 &2) to be differentially expressed (by both, unpaired Welch t-tests and paired t-tests at an FDR threshold of Q<0.1 according to the Benjaminin-Hochberg method). When comparing the normal epithelium with matching tumor invasion fronts we found 1128 genes to be differentially expressed according to both tests. The lists of differentially expressed genes are strongly overlapping: 923 genes (>80% of the smaller list) are differentially regulated in both tumor compartments (a full list of all genes, their expression data and annotations, and their statistical test results is available in Additional files 1 &2). This analysis proves that there are enormous differences in mRNA expression between colorectal carcinoma cells and their matching epithelia with more than 10% of all expressed genes being affected. The majority of these genes are deregulated in both compartments of colorectal tumors, the invasion front and the inner cell mass.
Does the functional annotation of the 923 commonly deregulated genes tell us something about cellular processes involved in colorectal tumor development? We clustered all differential genes (k-means; Euclidean distance; k = 2) into two clusters containing 508 up-regulated and 415 down-regulated genes. Both sets of genes were tested separately for significant overlap with gene sets from public databases using Fisher's Exact test (see Additional file 3). These databases capture information on signaling pathways and their downstream targets, clinical prognosis gene sets, genomic cancer gene neighborhoods and cellular structures and mechanisms. We found that a very high number of gene sets is over-represented among the 501 up-regulated genes (148 categories at p < 0.0004 and Q<0.01). Among these are many categories linked to proliferation or development of neoplastic processes, a functional link that has been described before numerous times . Surprisingly, we found several gene groups linked to proteasomal degradation to be over-represented among the up-regulated genes. This highlights the important role of the proteasome in cancer development that was recently proven by the development of the proteasome inhibitor Bortezomib . Our results suggest that proteasome inhibition could also be beneficial for the treatment of colorectal cancer especially in patients with up-regulated proteasomal genes. Furthermore, we found that gene sets previously described to be down-regulated in response to Rapamycin or HDAC inhibitors are over-represented among our 501 tumor up-regulated genes [16, 17]. This suggests that such drugs have the potential to partially revert the gene expression patterns that emerge during colorectal tumorigenesis. Also clinical prognosis-relevant gene sets were overrepresented among up-regulated genes, e.g. the breast cancer prognosis signature of van't Veer and coworkers that shares many genes with typical proliferation signatures [14, 18]. The top scoring gene group, however, was the coexpression neighborhood of the cancer gene RAN in an expression atlas of human tissues  which suggests a prominent role for this gene group in our cancer patients. The functional annotation of down-regulated genes in colorectal tumors resulted in a smaller number of significant functional categories: only 20 categories were over-represented at a relaxed threshold of p < 0.0006 (Q<0.05). Interestingly, in our set of colorectal tumors a similar set of genes is downregulated as that found by Sansom and coworkers after induction of mutant APC in a mouse model . APC is a well known component of the Wnt/beta-catenin pathway. The Wnt/beta-catenin pathway is often hyper-activated by mutation in colorectal cancers. This finding suggests that the Wnt/beta-catenin pathway may also be deactivated in our set of tumors. It raises the question whether loss rather than gain of expression upon Wnt/beta-catenin pathway activation is crucial for colorectal cancer development. In summary, the investigation of functional annotations of deregulated genes recovered some known functional aspects of colorectal tumors and highlights several novel routes to explore colorectal cancer biology and treatment.
We investigated the invasion front, the inner tumor mass, and surrounding normal epithelial tissue of colorectal tumors by laser-capture microdissection and microarray-based expression profiling. In comparisons of both tumor compartments with normal epithelium many genes were differentially expressed. The lists of deregulated genes in both compartments overlapped to a large extent. In contrast, cells from the invasion front and inner tumor mass did not show significant differences in their expression profile, neither on the single gene level nor on the pathway level. We conclude that largely similar genome-wide expression programs operate in the invasion front and interior compartment of a colorectal tumor.
Unselected consecutive CRC patients undergoing elective standard oncological resection at the Department of General, Vascular and Thoracic Surgery, Campus Benjamin Franklin, Charite, were prospectively recruited. The study was approved by the local ethical committee and informed consent was obtained from all patients.
Preprocessing of frozen tissue blocks by laser-capture microdissection was essentially performed as described in our previous publications [11–13]. Briefly described, all cancer specimens were snap frozen within 20 min following excision and snap frozen. During laser-capture microdissection frozen tissue specimens were serially cut into 6–8-mm-thick sections which were mounted on a sterile 2.5 mm membrane. Slides were fixed in 70% ethanol. The sections were briefly stained with haematoxylin and eosin, dehydrated in ethanol and dried for 10–15 min using an excicator. The membrane was turned around and fixed with adhesive tape on the other sterile slide. First slides served as a template on which the areas of tumour or normal epithelium were marked. On the consecutive section, these areas were microdissected using a laser microdissection system (SL, Jena, Germany and P.A.L.M. Microlaser Technologies AG Bernried, Germany) and capture transfer films (Arcturus GmbH, Moerfelden-Walldorf, Germany). For molecular analysis, up to 100,000 cells or approximately 30–60 mm2 of tissue section areas were pooled and collected in ice-cooled tubes containing 100 ml of 98% guanidine thiocyanate (GTC) buffer and 2% beta-mercaptoethanol. For molecular analysis, up to 100,000 cells were pooled. From each tumor we isolated cell populations of the invasion front, the inner cell mass and normal epithelium from the periphery.
Messenger RNA preparation and DNA chip hybridization
Poly AC RNA from the microdissected specimens was prepared using the PolyA-tract 1000 kit (Promega, Heidelberg, Germany) according to the manufacturer's recommendations. For each sample, the cDNA synthesis and repetitive in vitro transcription were performed three times. The total amount of prepared mRNA from each sample was used. First strand cDNA synthesis was initiated using the Affymetrix T7-oligo-dT promoter-primer combination at 0.1 mM. The second strand cDNA synthesis was generated by internal priming. In vitro transcription was performed using Ambion's Megascript kit (Ambion, Huntington, UK) as recommended by the manufacturer. From the generated cRNA, a new first strand synthesis was initiated using 0.025 mM of a random hexamer as primer. After completion, the second strand synthesis was performed using the Affymetrix T7-oligo-dT promoter-primer combination. A second in vitro transcription was performed and then the procedure was repeated one additional time. During the last in vitro transcription, biotin-labelled ribonucleotides were incorporated into the aRNA, as recommended by the Affymetrix protocol. Hybridisation and detection of the labelled cRNA on the Affymetrix Chip were performed according to Affymetrix standard protocol.
Microarray data preprocessing
Raw expression data was condensed to probe set-wise intensity values using the GC-RMA algorithm. Present/absent calls for each data point were calculated with the Affymetrix standard algorithm. Only genes with significant expression signals (Affymetrix "present calls" at alpha = 0.04) in a minimum of 30% of experiments were considered for subsequent analyses. For experiment normalization data were rescaled to have equal median expression intensities for all experiments, then intensities for each gene were divided by the average over all experiments with normal tissues and the logarithm of this ratio was calculated. Probe set annotation for U133A chips were retrieved from the Affymetrix web site (version 22). Gene-wise expression data were obtained by averaging intensities of all probe sets associated with a gene symbol, finally resulting in log ratio expression data for 7433 genes.
Expression data analysis
The preprocessed data were subjected to a principal component analysis (PCA) of the covariance matrix of the data to investigate and visualize global trends in the data. Hierarchical clustering using the complete linkage algorithm and Euclidean distances was used as a complementary method to analyze the grouping of samples. These algorithms were used as implemented in the Expressionist Analyst software (Version 4.1, Genedata, Basel). Pairwise Welch t-tests were performed for each gene to compare expression levels in the the sample groups invasion front (IT), inner tumor mass (RT) and normal epithelial tissue (N). Histograms of all resulting p values for each comparison were plotted using the statistical software R. The p value distributions helped to assess whether there are differences in expression on the genome level between the three sample groups. If there are no significant differences in expression (comparable to a situation when the data are randomized) the p value distribution resembles a uniform distribution.
- Guzińska-Ustymowicz K: The role of tumour budding at the front of invasion and recurrence of rectal carcinoma. Anticancer Res. 2005, 25: 1269-1272.PubMedGoogle Scholar
- Prall F: Tumour budding in colorectal carcinoma. Histopathology. 2007, 50: 151-162.View ArticlePubMedGoogle Scholar
- Liao D, Johnson RS: Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 2007, 26: 281-290.View ArticlePubMedGoogle Scholar
- Lester RD, Jo M, Montel V, Takimoto S, Gonias SL: Upar induces epithelial mesenchymal transition in hypoxic breast cancer cells. J Cell Biol. 2007, 178: 425-436.PubMed CentralView ArticlePubMedGoogle Scholar
- Baldus SE, Monig SP, Huxel S, Landsberg S, Hanisch F, Engelmann K, Schneider PM, Thiele J, Holscher AH, Dienes HP: Muc1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin Cancer Res. 2004, 10: 2790-2796.View ArticlePubMedGoogle Scholar
- Beiter K, Hiendlmeyer E, Brabletz T, Hlubek F, Haynl A, Knoll C, Kirchner T, Jung A: Beta-catenin regulates the expression of tenascin-c in human colorectal tumors. Oncogene. 2005, 24: 8200-8204.PubMedGoogle Scholar
- Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T, Ben-Ze'ev A: L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol. 2005, 168: 633-642.PubMed CentralView ArticlePubMedGoogle Scholar
- Hiendlmeyer E, Regus S, Wassermann S, Hlubek F, Haynl A, Dimmler A, Koch C, Knoll C, van Beest M, Reuning U, Brabletz T, Kirchner T, Jung A: Beta-catenin up-regulates the expression of the urokinase plasminogen activator in human colorectal tumors. Cancer Res. 2004, 64: 1209-1214.View ArticlePubMedGoogle Scholar
- Bertucci F, Salas S, Eysteries S, Nasser V, Finetti P, Ginestier C, Charafe-Jauffret E, Loriod B, Bachelart L, Montfort J, Victorero G, Viret F, Ollendorff V, Fert V, Giovaninni M, Delpero J, Nguyen C, Viens P, Monges G, Birnbaum D, Houlgatte R: Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene. 2004, 23: 1377-1391.View ArticlePubMedGoogle Scholar
- Miller LD, Liu ET: Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine. Breast Cancer Res. 2007, 9: 206-PubMed CentralView ArticlePubMedGoogle Scholar
- Groene J, Mansmann U, Meister R, Staub E, Roepcke S, Heinze M, Klaman I, Brümmendorf T, Hermann K, Loddenkemper C, Pilarsky C, Mann B, Adams H, Buhr HJ, Rosenthal A: Transcriptional census of 36 microdissected colorectal cancers yields a gene signature to distinguish UICC II and III. Int J Cancer. 2006, 119: 1829-1836.View ArticlePubMedGoogle Scholar
- Grützmann R, Pilarsky C, Ammerpohl O, Lüttges J, Böhme A, Sipos B, Foerder M, Alldinger I, Jahnke B, Schackert HK, Kalthoff H, Kremer B, Klöppel G, Saeger HD: Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia. 2004, 6: 611-622.PubMed CentralView ArticlePubMedGoogle Scholar
- Staub E, Gröne J, Mennerich D, Röpcke S, Klamann I, Hinzmann B, Castanos-Velez E, Mann B, Pilarsky C, Brümmendorf T, Weber B, Buhr H, Rosenthal A: A genome-wide map of aberrantly expressed chromosomal islands in colorectal cancer. Mol Cancer. 2006, 5: 37-PubMed CentralView ArticlePubMedGoogle Scholar
- Whitfield ML, George LK, Grant GD, Perou CM: Common markers of proliferation. Nat Rev Cancer. 2006, 6: 99-106.View ArticlePubMedGoogle Scholar
- Paramore A, Frantz S: Bortezomib. Nat Rev Drug Discov. 2003, 2: 611-612.View ArticlePubMedGoogle Scholar
- Mariadason JM, Corner GA, Augenlicht LH: Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin a, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res. 2000, 60: 4561-4572.PubMedGoogle Scholar
- Peng T, Golub TR, Sabatini DM: The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol. 2002, 22: 5575-5584.PubMed CentralView ArticlePubMedGoogle Scholar
- van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415: 530-536.View ArticlePubMedGoogle Scholar
- Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J, Soden R, Hayakawa M, Kreiman G, Cooke MP, Walker JR, Hogenesch JB: A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA. 2004, 101: 6062-6067.PubMed CentralView ArticlePubMedGoogle Scholar
- Sansom OJ, Reed KR, Hayes AJ, Ireland H, Brinkmann H, Newton IP, Batlle E, Simon-Assmann P, Clevers H, Nathke IS, Clarke AR, Winton DJ: Loss of apc in vivo immediately perturbs wnt signaling, differentiation, and migration. Genes Dev. 2004, 18: 1385-1390.PubMed CentralView ArticlePubMedGoogle Scholar
- Mootha VK, Lindgren CM, Eriksson K, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC: Pgc-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003, 34: 267-273.View ArticlePubMedGoogle Scholar
- Tian L, Greenberg SA, Kong SW, Altschuler J, Kohane IS, Park PJ: Discovering statistically significant pathways in expression profiling studies. Proc Natl Acad Sci USA. 2005, 102: 13544-13549.PubMed CentralView ArticlePubMedGoogle Scholar
- Zahn JM, Sonu R, Vogel H, Crane E, Mazan-Mamczarz K, Rabkin R, Davis RW, Becker KG, Owen AB, Kim SK: Transcriptional profiling of aging in human muscle reveals a common aging signature. PLoS Genet. 2006, 2: e115-PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.